Morgan Stanley’s Impact BioMedical IBO Stock Holding History
Bought
Maintained
Sold
Other funds holding IBO
Morgan Stanley's IBO Position: Q3 2026 in Review
Morgan Stanley increased its Impact BioMedical (IBO) stake by 0.27% in Q3 2026, buying an estimated $12 and bringing the position to 738 shares worth $4.13K. The position accounts for ﹤0.01% of the portfolio, ranked #7304.
Morgan Stanley first reported a position in IBO in Q3 2024 and has held it in 7 quarters since. The position peaked at $6.79K in Q1 2025. 19 funds tracked by Wall St. Rank hold IBO as of Q3 2026.
- Morgan Stanley held 738 shares of Impact BioMedical worth $4.13K as of Q3 2026.
- Morgan Stanley bought 2 Impact BioMedical shares in Q3 2026, an estimated $12.
- Impact BioMedical made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #7304 holding.
- Morgan Stanley first reported a position in Impact BioMedical in Q3 2024 and has held it in 7 quarters since.
- Morgan Stanley's Impact BioMedical position peaked at $6.79K in Q1 2025.
- 19 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.
Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.